Sagimet Biosciences Inc. Class A (SGMT)

NASDAQ:
SGMT
| Latest update: Apr 15, 2026, 7:03 PM

Stock events for Sagimet Biosciences, Inc. (SGMT)

Over the past six months, Sagimet announced positive results from a Phase 1 clinical trial and its license partner's NDA acceptance in China. Sagimet entered a license agreement with TAPI Technology & API Services. Barclays initiated coverage with an "Equal-Weight" rating, contributing to a stock decrease. Insider selling occurred by the CEO. Sagimet reported its fourth quarter and full year 2025 financial results, with a moderate positive market reaction. The company announced participation in investor conferences and presentations at the Fueling MASH Keystone Symposium.

Demand Seasonality affecting Sagimet Biosciences, Inc.’s stock price

Sagimet Biosciences, Inc. does not exhibit typical demand seasonality as a clinical-stage biopharmaceutical company. Its revenue is tied to milestones in drug development and clinical trial progress, not seasonal consumer purchasing patterns.

Overview of Sagimet Biosciences, Inc.’s business

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics, specifically fatty acid synthase (FASN) inhibitors, to target dysfunctional metabolic and fibrotic pathways. Their lead drug candidate, Denifanstat, is in development for MASH, acne, and select cancers, having achieved positive results in a Phase 2b clinical trial and Breakthrough Therapy designation from the FDA for non-cirrhotic MASH. The company is also exploring TVB-3567 for acne and oncology programs.

SGMT’s Geographic footprint

Sagimet Biosciences Inc. is headquartered in San Mateo, California, United States. They have a license partner in China, Ascletis Bioscience Co. Ltd., for the development of denifanstat in moderate to severe acne.

SGMT Corporate Image Assessment

Sagimet Biosciences' brand reputation is shaped by its clinical development progress and scientific presentations. Positive results from the Phase 2b FASCINATE-2 trial and FDA Breakthrough Therapy designation enhance its standing. Participation in healthcare conferences and analyst ratings contribute to a generally positive market perception.

Ownership

Sagimet Biosciences Inc. has a diverse ownership structure, including institutional owners such as Vanguard Group Inc and Blue Owl Capital Holdings LP, holding a total of 14,423,817 shares. Individual investors own 46% of the shares, and insiders own shares valued at US$15 million. Key individual and insider owners include Patrick J. Kerins, Forest Baskett, and CEO David Happel.

Expert AI

Show me the sentiment for Sagimet Biosciences, Inc.
What's the latest sentiment for Sagimet Biosciences, Inc.?

Price Chart

$5.95

7.31%
(1 month)

Top Shareholders

The Vanguard Group, Inc.
4.10%
Blue Owl Capital, Inc.
4.01%
Affinity Asset Advisors LLC
3.70%
Woodline Partners Holdings LP
3.23%
Baker Bros. Advisors LP
3.07%
BlackRock, Inc.
2.63%
MW Group LP
2.52%
Hillhouse Capital Group Ltd.
2.34%

Trade Ideas for SGMT

Today

Sentiment for SGMT

News
Social

Buzz Talk for SGMT

Today

Social Media

FAQ

What is the current stock price of Sagimet Biosciences, Inc.?

As of the latest update, Sagimet Biosciences, Inc.'s stock is trading at $5.95 per share.

What’s happening with Sagimet Biosciences, Inc. stock today?

Today, Sagimet Biosciences, Inc. stock is up by 7.31%, possibly due to news.

What is the market sentiment around Sagimet Biosciences, Inc. stock?

Current sentiment around Sagimet Biosciences, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Sagimet Biosciences, Inc.'s stock price growing?

Over the past month, Sagimet Biosciences, Inc.'s stock price has increased by 7.31%.

How can I buy Sagimet Biosciences, Inc. stock?

You can buy Sagimet Biosciences, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol SGMT

Who are the major shareholders of Sagimet Biosciences, Inc. stock?

Major shareholders of Sagimet Biosciences, Inc. include institutions such as The Vanguard Group, Inc. (4.10%), Blue Owl Capital, Inc. (4.01%), Affinity Asset Advisors LLC (3.70%) ... , according to the latest filings.